1. Scrip
  2. >>New Products

AZ’s ZS-9 Targets Hyperkalemia Sector As It Nears EU Market

 
• By John Davis

A potential near-blockbuster drug, AstraZeneca’s Lokelma (ZS-9), has received a positive opinion from Europe’s CHMP and, if approved, will soon have to justify best-in-class plaudits and a hefty acquisition price.

Zirconium crystal

AstraZeneca PLC’s investigational hyperkalemia therapy, Lokelma (ZS-9, sodium zirconium cyclosilicate), has received a positive opinion from the EU’s Committee for Medicinal Products for Human Use (CHMP), and if it is approved, could become a high-selling product through satisfying an unmet need in the therapeutic sector.

The UK big pharma spent $2.7bn on acquiring the US company, ZS Pharma Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

GSK Pays $1.2bn For Phase III-Ready MASH Contender

 
• By Andrew McConaghie

The acquisition of Boston Pharma’s once-a-month FGF21 analog adds to GSK’s liver disease portfolio.